| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background and Objective: While
tyrosine kinase inhibitors (TKIs) have transformed CP-CML management,
limited data exist on their use in clinical practice.
|Table 1. Characteristics and outcomes of patients treated in second line|
|Table 2. Characteristics and outcomes of patients treated in third line|
|Figure 1. a) Kaplan Mayer survival curves for patients treated in second line in the overall population b) Kaplan Mayer survival curves for patients treated in second line in the population stratified according to their treatment with CLARA or with the control group|